



Accelovance, Inc. Continues European Expansion with Acquisition of THERAMetrics AG's CRO Services

ROCKVILLE, MD – May 25, 2016 – Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in vaccines, oncology, and general medicine announced today further expansion of European CRO services with the acquisition of THERAMetrics Holding AG's (THERAMetrics) three CRO subsidiaries and Phase I unit in Germany, Italy, and Romania. In addition to the employees and facilities associated with these European subsidiaries, Accelovance will also assume management of THERAMetrics' ongoing clinical program work in the United States.

Stephen J. Trevisan, CEO of Accelovance noted, "Accelovance is excited to continue its European expansion into Germany, Italy, and Romania and to welcome the addition of these talented employees to the Accelovance family. We appreciate the important opportunity to continue working on the valuable assets of THERAMetrics' current sponsors, and look forward to supporting their needs in successfully delivering on their programs."

Raffaele Petrone, Chairman and CEO of THERAMetrics stated, "I am pleased to announce this important transaction with Accelovance. Not only does it mark the beginning of THERAMetrics' operational transformation, it gives our CRO business, and its employees, the opportunity to thrive under the leadership of a strong global player in the CRO industry."

The acquisition adds to Accelovance's European and service expansion efforts over the last two years with the acquisition and integration of service providers Altair Clinical and Clinquest, Inc. & BV.

About THERAMetrics Holding AG

THERAMetrics Holding AG is a global technology-based contract research and development organization dedicated to providing a full range of technological solutions through the entire value chain of drug discovery and development. The company is listed on the SIX Swiss Exchange under the symbol TMX and is headquartered in Stans, Switzerland.

About Accelovance, Inc.

Accelovance, Inc., headquartered in Rockville, MD, is an industry award-winning global Contract Research Organization (CRO) focused primarily in vaccine, oncology, and general medicine clinical research. As a clinical services provider to the pharmaceutical and biotechnology industries, Accelovance offers comprehensive clinical development services including management and implementation of Phase I-IV clinical trials, supportive research centers, and a clinical engagement solution utilized for recruitment, post-marketing surveillance, and long-term survival follow-up. For more information, visit the company's Web site at www.accelovance.com.

###

Press Contact: Michael Keens, VP Business Development
Accelovance, Inc.
240.238.4941
mkeens@accelovance.com
Twitter: @Accelovance

Raffaele Petrone, Investor and External Relations
THERAMetrics Holding AG
+41 (0)44 723 59 59
investor@therametrics.com